» Articles » PMID: 35246061

D-dimer As a Predictor of Cardiovascular Outcomes in Patients with Diabetes Mellitus

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aimed to investigate the association between D-dimer and cardiovascular diseases outcomes in patients with type 2 diabetes.

Methods: This is a single-center retrospective cohort study which was performed in a population who had health examinations between 2010 and 2015 in Jiangxi Provincial People's Hospital. All adult patients who were diagnosed with type 2 diabetes were screened. The cardiovascular diseases events were defined as all-cause mortality, new cardiovascular diseases incidence (acute myocardial infarction, unstable angina, stroke), or cardiovascular mortality.

Results: The median age was 59.6 years; 50.1% of participants were women; D-dimer was significantly associated with endpoint events. After multivariable adjustment for form of treatments and traditional risk factors, the odds ratio was 3.62 (95% CI 2.07-6.03) for the highest quartile of D-dimer with the lowest quartile as reference. Meanwhile, higher D-dimer levels were associated with a significant and independent higher risk of cause-specific cardiovascular disease events.

Conclusion: High plasma concentrations of D-dimer were associated with increased risk of cardiovascular diseases events in patients with type 2 diabetes, even after adjusting for cardiovascular risk factors and form of treatments. Measurement of D-dimer may lead to a practical improvement in the current risk stratification criteria for patients with type 2 diabetes.

Citing Articles

Deciphering key roles of B cells in prognostication and tailored therapeutic strategies for lung adenocarcinoma: a multi-omics and machine learning approach towards predictive, preventive, and personalized treatment strategies.

Zhang J, Hu D, Fang P, Qi M, Sun G EPMA J. 2025; 16(1):127-163.

PMID: 39991096 PMC: 11842682. DOI: 10.1007/s13167-024-00390-4.


Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.

Valencia I, Lumpuy-Castillo J, Magalhaes G, Sanchez-Ferrer C, Lorenzo O, Peiro C Cardiovasc Diabetol. 2024; 23(1):75.

PMID: 38378550 PMC: 10880237. DOI: 10.1186/s12933-023-02097-8.


Association between N-terminal pro-B-type natriuretic peptide and clinical outcomes in bedridden patients with stroke: a cross-sectional study.

Li D, Zhou M, Zha F, Long J, Wang Y BMJ Open. 2024; 14(1):e077083.

PMID: 38286702 PMC: 10826584. DOI: 10.1136/bmjopen-2023-077083.


How we manage a high D-dimer.

Franchini M, Focosi D, Pezzo M, Mannucci P Haematologica. 2023; 109(4):1035-1045.

PMID: 37881856 PMC: 10985443. DOI: 10.3324/haematol.2023.283966.


Associations Between Mean Platelet Volume and Various Factors in Type 2 Diabetes Patients: A Single-Center Study from Poland.

Gacuta K, Koper-Lenkiewicz O, Milewska A, Cwiklinska-Dworakowska M, Matowicka-Karna J, Kaminska J Med Sci Monit. 2023; 29:e941109.

PMID: 37649249 PMC: 10478580. DOI: 10.12659/MSM.941109.


References
1.
Di Castelnuovo A, De Curtis A, Costanzo S, Persichillo M, Olivieri M, Zito F . Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica. 2013; 98(9):1476-80. PMC: 3762106. DOI: 10.3324/haematol.2012.083410. View

2.
Long Z, Qu G, Xu M . [Relationship between the level of plasma D-dimer and diabetic microangiopathy]. Hunan Yi Ke Da Xue Xue Bao. 2003; 26(5):434-6. View

3.
Soares A, Rosario P, Borges M, Sousa M, Fernandes A, Carvalho M . PAI-1 and D-dimer in type 2 diabetic women with asymptomatic macrovascular disease assessed by carotid Doppler. Clin Appl Thromb Hemost. 2009; 16(2):204-8. DOI: 10.1177/1076029609334626. View

4.
Adam S, Key N, Greenberg C . D-dimer antigen: current concepts and future prospects. Blood. 2008; 113(13):2878-87. DOI: 10.1182/blood-2008-06-165845. View

5.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View